具体到财务数据上，2024年和2025年，该公司营收分别为2.36亿元、2.86亿元，净利润（调整后）分别 为929.37万元、2360.23万元。整体毛利率约70%。 2月26日，爱博医疗股价小幅波动，收盘价报62.40元/股，涨2.36%，当下市值121亿元。 据本次公告，德美医疗成立于2016年，是国内运动医学领域公司，销售网络覆盖国内和东南亚、拉丁美 洲、中东、欧洲等海外区域。此前，该公司钛合金带线锚钉、PEEK带线锚钉等多款产品在第四批国家 高值耗材集采中中标。从集采申报需求量看，外资品牌仍占较高市场份额，德美医疗则是国内运动医学 领域前三品牌。 智通财经编辑 | 谢欣 2月25日盘后，爱博医疗公告拟收购德美医疗68.31%股权，交易对价为6.83亿元。交易完成后，德美医 疗将成为前者控股子公司，并纳入爱博医疗报表。 智通财经记者 | 陈杨 | | | | 标的资产类型 | 股权资产 | | | --- | --- | --- | | 本次交易股权比例(%) | | 68.31% | | 是否经过审计 | □是 ☑否 | | | 审计机构名称 | 北京和瑞吉会计师事务所有限公司 | | | 项目 | ...

眼科器械龙头爱博医疗（688050）拟通过并购切入运动医学领域。在前次披露投资意向一个月后，公司于2月26日发布具体 收购方案，拟以6.83亿元收购德美联合（重庆）医疗科技有限公司（以下简称"德美医疗"）68.31%股权。交易作价较净资 产账面值溢价约3倍，预计将形成约5亿元商誉。资金方面，约70%至80%来自银行并购贷款。 针对市场对杠杆收购的关注，爱博医疗相关负责人于2月26日向北京商报记者回应称，目前公司账面自有资金较为充裕，回 款情况良好，且国家对并购贷款有相应的支持政策，合理使用财务杠杆不会构成较大压力。 近年来，德美医疗所处的运动医学赛道发展迅速。经营数据显示，2025年，德美医疗营收和净利润均实现较快增长。在当 前爱博医疗业绩增速放缓的背景下，此次收购能否为公司注入新的增长动力，记者将持续关注。 贷款比例预计为70%—80% 爱博医疗最新公告显示，公司拟使用并购贷款及自有资金收购德美医疗68.31%股权，本次交易对价为6.83亿元。公司支付 第一期股转款后，本次交易涉及的德美医疗股权将全部完成办理工商变更登记，公司将享有作为目标公司股东的全部权利 和权益，德美医疗将成为公司控股子公司，纳入公司合 ...

眼科器械龙头爱博医疗（688050）拟通过并购切入运动医学领域。在前次披露投资意向一个月后，公司于2月26日发布具体 收购方案，拟以6.83亿元收购德美联合（重庆）医疗科技有限公司（以下简称"德美医疗"）68.31%股权。交易作价较净资 产账面值溢价约3倍，预计将形成约5亿元商誉。资金方面，约70%至80%来自银行并购贷款。 针对市场对杠杆收购的关注，爱博医疗相关负责人于2月26日向北京商报记者回应称，目前公司账面自有资金较为充裕，回 款情况良好，且国家对并购贷款有相应的支持政策，合理使用财务杠杆不会构成较大压力。 近年来，德美医疗所处的运动医学赛道发展迅速。经营数据显示，2025年，德美医疗营收和净利润均实现较快增长。在当 前爱博医疗业绩增速放缓的背景下，此次收购能否为公司注入新的增长动力，记者将持续关注。 爱博医疗最新公告显示，公司拟使用并购贷款及自有资金收购德美医疗68.31%股权，本次交易对价为6.83亿元。公司支付 第一期股转款后，本次交易涉及的德美医疗股权将全部完成办理工商变更登记，公司将享有作为目标公司股东的全部权利 和权益，德美医疗将成为公司控股子公司，纳入公司合并报表范围。 公告显示，德美医 ...

Group 1 - The core point of the article is that Aibo Medical plans to acquire at least 51% of the shares of Demei Medical to expand its presence in the healthcare sector [1][2] - Aibo Medical intends to invest up to 1 billion yuan through a combination of acquisition loans and its own funds for the acquisition [2] - Demei Medical is a leading company in the sports medicine field in China, recognized as a national high-tech enterprise with 276 patented technologies [2][3] Group 2 - Aibo Medical is facing challenges in its core business areas, particularly in the OK lens and artificial lens sectors, which have seen significant price drops and negative impacts on performance [3][4] - The acquisition aims to create a dual-channel strategy combining ophthalmology and sports medicine, but there are concerns about the financial performance of Demei Medical post-acquisition [3][4] - Demei Medical's projected revenue is expected to grow from 178 million yuan in 2023 to 286 million yuan in 2025, with a turnaround from a loss of 7.08 million yuan to a profit of 23.6 million yuan [4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return that exceeds the market benchmark by more than 5% to 20% over the next 6-12 months [4][9]. Core Insights - The company achieved a total revenue of 653 million yuan in the first half of 2025, representing a year-on-year growth of 1.72%, while the net profit attributable to shareholders reached 38 million yuan, up 33.37% year-on-year [1][4]. - The company's self-owned product revenue increased to 203 million yuan, a growth of 14.04% year-on-year, accounting for 31.09% of total revenue, with significant contributions from self-produced artificial crystals [1][2]. - The company has a robust R&D investment strategy, with R&D expenses amounting to 434 million yuan in the first half of 2025, a 23.6% increase year-on-year, representing 21.4% of self-owned product revenue [2][4]. Financial Performance Summary - For the fiscal years 2025 to 2027, the company is projected to achieve revenues of 1.564 billion, 1.715 billion, and 1.875 billion yuan, with respective growth rates of 9.48%, 9.67%, and 9.33% [2][8]. - The net profit attributable to shareholders is expected to grow to 135 million, 180 million, and 214 million yuan over the same period, with growth rates of 45.85%, 33.71%, and 18.99% respectively [2][8]. - The earnings per share (EPS) are projected to be 0.91, 1.22, and 1.45 yuan for 2025, 2026, and 2027, respectively [2][8].

Company Developments - China Telecom and Alibaba have reached a strategic cooperation agreement to jointly serve Chinese enterprises going global, focusing on cloud and AI infrastructure, e-commerce services, and social value innovation [2] - Bawang Tea has officially entered the Philippine market with three stores opening in the Manila metropolitan area, selling over 23,000 cups in the first three days, marking its seventh international market [2] - KUKA Home plans to invest approximately 1.12 billion yuan to build a self-owned base in Indonesia, expecting an annual revenue of about 2.52 billion yuan upon completion [3] - Stone Technology has achieved the number one global market share in both cleaning robots and vacuum robots for the first half of 2025, with shares of 15.2% and 20.7% respectively [3] - Alibaba's AliExpress is preparing a high-profile brand export project, inviting top global brands to participate, with aggressive growth targets set [3] - Gaode Map has launched ride-hailing services in Canada, New Zealand, Switzerland, and the UAE, expanding its international presence [4] - Xiaomi aims to make 2025 the year for the international expansion of its home appliances and new retail, with plans for automotive exports by 2027 [4] - JD Industrial has signed agreements with two Brazilian companies to enhance the digital supply chain services in the region [5] - BYD has reported that seven out of eight roll-on/roll-off ships are now operational, with significant sales in multiple countries [5] - Proton, supported by Geely, has launched its first electric vehicle factory in Malaysia, with an investment of approximately 138 million yuan [5] Investment and Financing - UBTECH has secured a strategic financing credit line of $1 billion to establish a super factory in the Middle East [6] - Laimu Technology has completed several rounds of financing exceeding 100 million yuan, focusing on the European and American markets for smart lawn mowers [6] - Ruijian Pharmaceutical has raised over 300 million yuan in B-round financing, with plans to accelerate clinical development of Parkinson's treatment products [7] - Ronovo Surgical has completed a D-round financing of $67 million, aiming to expand its modular surgical robot platform globally [7] - Sierra Medical has raised over 100 million yuan to accelerate the development of its ophthalmic products and expand its market presence [8]

Core Viewpoint - The company reported strong revenue growth in 2024, but faced a decline in net profit in Q1 2025 due to market pressures from centralized procurement and reduced surgical volumes [1][2]. Financial Performance - In 2024, the company achieved revenue of 1.41 billion yuan, a year-on-year increase of 48.24%, and a net profit of 388 million yuan, up 27.77% [1]. - For Q1 2025, revenue was 357 million yuan, reflecting a year-on-year growth of 15.07%, while net profit decreased to 93 million yuan, down 10.05% [1]. Product Performance - Revenue from artificial crystalline lenses reached 588 million yuan in 2024, growing by 17.66%, with sales volume increasing by 44.93% [2]. - The company’s revenue from myopia control products grew by 20.79%, driven by the introduction of various new products [2]. R&D Investment and New Business Growth - The company increased R&D investment to 160 million yuan in 2024, a rise of 20.80%, representing 11.33% of total revenue [3]. - The contact lens business saw significant growth, with revenue reaching 426 million yuan, a staggering increase of 211.84% [3]. Market Outlook - The company is projected to achieve revenues of 1.81 billion yuan, 2.26 billion yuan, and 2.79 billion yuan for 2025-2027, with respective growth rates of 28.44%, 24.91%, and 23.12% [4]. - Expected net profits for the same period are 467 million yuan, 600 million yuan, and 778 million yuan, with growth rates of 20.21%, 28.55%, and 29.63% [4]. Earnings Per Share - The projected EPS for the years 2025, 2026, and 2027 are 2.46 yuan, 3.17 yuan, and 4.10 yuan respectively [5].

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 近日，全球领先的眼科手术设备公司 BVI Medical 宣布，公司已完成与资产管理公司 TPG 合作， 筹集了 10亿美元 （约72.45亿人民币）的战略 资本 ，此次融资或为近年来 眼科器械领域最大的一笔融资 。 BVI 通过本轮融资 偿还了现有债务 ，并 增加来自 TPG 和新投资者的股权， 优化了公司的资本结构 ，降低财务杠杆，并能够更灵活地投入研发、 生产扩张以及市场拓展，助力公司 加速产品开发并扩大其全球业务版图 。 TPG 管理资产总额超过2460亿美元，此次对 BVI 的投资不仅彰显了其对眼科医疗市场的信心，也标志着 BVI 在挑战爱尔康、蔡司等眼科巨头的市 场地位上迈出了重要一步 。 BVI 的业务涵盖眼科手术器械、人工晶体、微创手术设备等多个细分市场，覆盖全球90 多个国家。 旗下核心产品包括人工晶体系列 ，特别是 FINEVISION®系列 和SERENITY ®系列 。 FineVision有 疏水性材料与亲水性材料 ...